Cascade of levodopa dose and weight-related dyskinesia in Parkinson's disease (LD-WD-PD cascade).
We have studied a cohort of 220 Parkinson's disease (PD) patients for risk factors of developing new dyskinesia. Twenty-nine patients were noticed to have developed new dyskinesia at the second assessment. The dyskinetic patients received significantly higher maximum level daily dose of levodopa. These patients had lost weight during the course of the disease from 72+/-15 to 66+/-17kg, p=0.002. The dyskinetic patients received significantly higher daily dose of levodopa per kilogram body weight, 8.4+/-3.5mg/kg vs. 6.0+/-3.9mg, p=0.003. Weight-losers PD patients developed significantly more dyskinesia than non-weight losers-p=0.002. Logistic regression analysis revealed weight loss and daily levodopa dose per kilogram body weight to be the only significant factors for dyskinesia in addition to disease duration. There was a "dose response to developing dyskinesia" according to the increasing levodopa dose per kilogram body weight.
Sharma
Jagdish C
JC
Parkinson's Disease Services, Sherwood Forest Hospitals NHS Trust, Bournemouth, BH7 7 DW, UK. Jagdish.Sharma@sfh-tr.nhs.uk
Macnamara
Lorna
L
Hasoon
Mohammad
M
Vassallo
Michael
M
Ross
Ian
I
D000368:Aged; D000369:Aged, 80 and over; D000978:Antiparkinson Agents / Q000009:adverse effects*; D015331:Cohort Studies; D004305:Dose-Response Relationship, Drug; D004409:Dyskinesia, Drug-Induced / Q000209:etiology*; D005260:Female; D006801:Humans; D007980:Levodopa / Q000009:adverse effects*; D016015:Logistic Models; D008297:Male; D010300:Parkinson Disease / Q000188:drug therapy / Q000503:physiopathology; D012189:Retrospective Studies; D012307:Risk Factors; D012737:Sex Factors; D015431:Weight Loss / Q000187:drug effects
D000978:Antiparkinson Agents; D007980:Levodopa